Consensus guidelines for the management of plaque psoriasis
- PMID: 22250239
- DOI: 10.1001/archdermatol.2011.1410
Consensus guidelines for the management of plaque psoriasis
Abstract
The Canadian Guidelines for the Management of Plaque Psoriasis were reviewed by the entire National Psoriasis Foundation Medical Board and updated to include newly approved agents such as ustekinumab and to reflect practice patterns in the United States, where the excimer laser is approved for psoriasis treatment. Management of psoriasis in special populations is discussed. In the updated guidelines, we include sections on children, pregnant patients or pregnant partners of patients, nursing mothers, the elderly, patients with hepatitis B or C virus infections, human immunodeficiency virus-infected patients, and patients with malignant neoplasms, as well as sections on tumor necrosis factor blockers, elective surgery, and vaccinations.
Similar articles
-
National Psoriasis Foundation clinical consensus on disease severity.Arch Dermatol. 2007 Feb;143(2):239-42. doi: 10.1001/archderm.143.2.239. Arch Dermatol. 2007. PMID: 17310004
-
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.J Am Acad Dermatol. 2008 Jan;58(1):94-105. doi: 10.1016/j.jaad.2007.08.030. Epub 2007 Nov 5. J Am Acad Dermatol. 2008. PMID: 17980456
-
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.J Am Acad Dermatol. 2010 Feb;62(2):291-9. doi: 10.1016/j.jaad.2009.03.047. Epub 2009 Jul 31. J Am Acad Dermatol. 2010. PMID: 19646777 Review.
-
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation.J Am Acad Dermatol. 2009 Dec;61(6):1044-55. doi: 10.1016/j.jaad.2009.03.044. Epub 2009 Oct 7. J Am Acad Dermatol. 2009. PMID: 19811848 Review.
-
Pilot evaluation of supra-erythemogenic phototherapy with excimer laser in the treatment of patients with moderate to severe plaque psoriasis.J Dermatolog Treat. 2010 Jan;21(1):54-60. doi: 10.3109/09546630903203756. J Dermatolog Treat. 2010. PMID: 19711219 Clinical Trial.
Cited by
-
Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients.Tunis Med. 2022 Janvier;100(1):49-55. Tunis Med. 2022. PMID: 35822332 Free PMC article.
-
Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.Indian Dermatol Online J. 2020 Jan 13;11(1):51-57. doi: 10.4103/idoj.IDOJ_169_19. eCollection 2020 Jan-Feb. Indian Dermatol Online J. 2020. PMID: 32055509 Free PMC article.
-
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.J Dermatol. 2021 Nov;48(11):1652-1664. doi: 10.1111/1346-8138.16068. Epub 2021 Aug 15. J Dermatol. 2021. PMID: 34396569 Free PMC article.
-
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. J Dermatol. 2017. PMID: 28391657 Free PMC article. Clinical Trial.
-
Efficacy of Methotrexate in patients with plaque type psoriasis.Pak J Med Sci. 2014 Sep;30(5):1050-3. doi: 10.12669/pjms.305.4451. Pak J Med Sci. 2014. PMID: 25225524 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical